AGM
CAPR icon

Alpine Global Management’s Capricor Therapeutics CAPR Stock Holding History

Alpine Global Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,168
Closed -$115K – 207
2024
Q2 		$115K Buy
+24,168
New +$135K 0.02% 388

Other funds holding CAPR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Alpine Global Management's CAPR Position: Q3 2024 in Review

Alpine Global Management sold out of Capricor Therapeutics (CAPR) in Q3 2024, closing a stake of 24,168 shares — an estimated $115K sold.

Alpine Global Management first reported a position in CAPR in Q2 2024 and held it in 1 quarter. The position peaked at $115K in Q2 2024. 75 funds tracked by Wall St. Rank hold CAPR as of Q3 2024.

  • Alpine Global Management reported no remaining Capricor Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Alpine Global Management sold 24,168 Capricor Therapeutics shares in Q3 2024, an estimated $115K.
  • Alpine Global Management first reported a position in Capricor Therapeutics in Q2 2024 and held it in 1 quarter.
  • Alpine Global Management's Capricor Therapeutics position peaked at $115K in Q2 2024.
  • 75 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2024.

Based on Alpine Global Management's 13F filing for Q3 2024, filed 14 Nov 2024.